Eli Lilly and Company (NYSE:LLY) Shares Climb 3.1% Following Better-Than-Expected Earnings

Key Points

• Eli Lilly shares rose 3.1% after the company reported quarterly EPS of $7.48 and revenue of $24.4 billion, exceeding analyst estimates; revenue increased 38.6% year over year.
• Growth was driven by strong demand for its GLP-1 drugs, with Mounjaro sales up 65% to $10.7 billion and Zepbound revenue reaching $5.35 billion. Lilly also raised its 2026 revenue outlook to $91 billion–$92 billion.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating, though the stock’s high valuation and reliance on GLP-1 products leave it exposed to pricing pressure, coverage changes and a potential slowdown in obesity-drug growth.

Eli Lilly and Company (NYSE:LLY - Get Free Report) shot up 3.1% during trading on Friday following a better than expected earnings announcement. The company traded as high as $1,449.68 and last traded at $1,415.64. Approximately 5,030,224 shares changed hands during trading, an increase of 71% from the average session volume of 2,942,995 shares. The stock had previously closed at $1,373.70.

The company reported $7.48 earnings per share for the quarter, topping analysts' consensus estimates of $5.68 by $1.80. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company's revenue was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $7.02 EPS.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio is 23.22%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong quarterly results: Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted EPS of $7.48 significantly exceeded analysts’ expectations. Mounjaro sales climbed 65% to $10.7 billion and Zepbound generated $5.35 billion in revenue, demonstrating robust demand for Lilly’s GLP-1 treatments. Lilly reports third-quarter 2026 financial results
• Positive Sentiment: Higher outlook: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion, supported by sustained Mounjaro and Zepbound demand, broader Medicare access and growing middle-income adoption.
• Positive Sentiment: Pipeline support: Positive Phase 3 results for experimental obesity and diabetes drug retatrutide, including performance versus Ozempic, strengthened expectations for Lilly’s next generation of metabolic treatments. Management also pointed to expanding opportunities in oncology, immunology and neuroscience. Eli Lilly retatrutide trial results
• Positive Sentiment: Analyst optimism: Scotiabank, Morgan Stanley and RBC raised their price targets to $1,605, $1,596 and $1,600, respectively, while maintaining positive ratings. These revisions signal confidence that earnings growth can support further appreciation.
• Neutral Sentiment: Valuation and concentration: Lilly’s market capitalization is now comparable to Berkshire Hathaway’s, but roughly two-thirds of revenue is tied to GLP-1 products. The company’s elevated valuation leaves the stock sensitive to any slowdown in obesity-drug growth.
• Negative Sentiment: Pricing and one-time items: Realized prices fell about 15%, although a 53% increase in volume more than offset the decline. Approximately $900 million of quarterly benefits may not recur, while acquisition-related charges pressured reported earnings. Potential employer resistance to covering weight-loss drugs remains an additional risk.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. TD Cowen reissued a "buy" rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Leerink Partners raised their price objective on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an "outperform" rating in a report on Wednesday, October 21st. Argus lifted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a research report on Friday. The Goldman Sachs Group reiterated a "buy" rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Finally, Scotiabank increased their target price on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,391.29.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by insiders.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its holdings in Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp boosted its holdings in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after buying an additional 605,752 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after buying an additional 137,364 shares during the period. Finally, Jennison Associates LLC grew its position in shares of Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after buying an additional 400,538 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company's 50 day moving average is $1,194.34 and its 200-day moving average is $1,090.89. The company has a market capitalization of $1.33 trillion, a P/E ratio of 47.50, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.